Novo Nordisk stock pops on Phase 1 data for new weight loss drug amycretin
- Posted on January 24, 2025
- By AOL
- 3 Views
Novo Nordisk stock pops on Phase 1 data for new weight loss drug amycretin
Novo Nordisk announces new early clinical trial data for its latest weight loss drug, amecrytin.
